This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the efficacy and acceptability of single agent CPAs for the prevention of primary breast cancer, in unaffected women, at an above average risk of developing breast cancer. Using a network meta-analysis, we also intend to rank single CPAs, based on their efficacy and acceptability (an endpoint that is defined as the inverse of CPA-related toxicity). © 2016 The Cochrane Collaboration.
Risk-reducing medication for primary breast cancer: A network meta-analysis
Mocellin, Simone;Pasquali, Sandro
2016
Abstract
This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the efficacy and acceptability of single agent CPAs for the prevention of primary breast cancer, in unaffected women, at an above average risk of developing breast cancer. Using a network meta-analysis, we also intend to rank single CPAs, based on their efficacy and acceptability (an endpoint that is defined as the inverse of CPA-related toxicity). © 2016 The Cochrane Collaboration.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
